Search the Newsreel

Axsome Therapeutics, Inc. $AXSM Stock Holdings Reduced by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 3.5% in the first quarter, though it still holds a significant position. Axsome Therapeutics reported mixed quarterly results, beating revenue expectations but missing on earnings per share. Despite the mixed results and …

Axsome gains as narcolepsy therapy undergoes FDA review

Axsome Therapeutics' stock rose after the FDA accepted its New Drug Application for solriamfetol for narcolepsy, setting a PDUFA date for February 12, 2026. The therapy has shown promise in improving wakefulness and reducing excessive daytime sleepiness in narcolepsy patients. This marks a positive …

Somnigroup International Inc. $SGI Shares Bought by Dorsey Wright & Associates

Somany Ceramics FY 2025-26 Annual Report: Revenue Grows 4.9%, PAT Rises 35% to ₹8,119 Lakhs

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL)

Three analysts have issued bullish sentiments on several healthcare companies. Andrew Tsai from Jefferies maintained a Buy rating on Axsome Therapeutics with a $380.00 price target, while Ami Fadia from Needham maintained a Buy rating on Harmony Biosciences Holdings with a $45.00 price target. …

Responsive Playbooks and the AXSM Inflection

This article analyzes Axsome Therapeutics Inc. (NASDAQ: AXSM), highlighting weak near-term sentiment but strong long-term potential. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, and details multi-timeframe signal analysis with specific support and resistance levels. The analysis …

Axsome's AXS-12 Advances to FDA Review for Cataplexy

The FDA has accepted Axsome Therapeutics' New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in patients with narcolepsy, setting a PDUFA target action date of May 1, 2027. AXS-12 aims to be a non-scheduled, orally dosed option for daytime use, distinct …

Axsome Therapeutics (AXSM) Wins FDA Acceptance For AXS 12 In Narcolepsy Cataplexy

Axsome Therapeutics (AXSM) has received FDA acceptance for its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy patients, with a target decision date set and no advisory committee meeting planned. This regulatory milestone provides increased visibility for investors, potentially expanding …

Axsome FDA application accepted for 2027 target date

Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy. This acceptance sets a formal target action date of May 1, 2027, for the drug, which is designed to address the sudden loss …

Axsome gets FDA filing acceptance for narcolepsy drug AXS-12

Axsome Therapeutics has announced that the FDA has accepted its New Drug Application for AXS-12 (reboxetine) to treat cataplexy in narcolepsy patients, setting a target action date of May 1, 2027. The drug, which has Orphan Drug Designation, targets the sudden muscle tone loss …

Axsome gains FDA review for narcolepsy therapy (AXSM:NASDAQ)

Axsome Therapeutics' shares rose in premarket trading after the U.S. FDA accepted its marketing application for AXS-12 (reboxetine), an experimental therapy for narcolepsy. This marks a significant step for the neurology drug developer in bringing its treatment to market.

FDA accepts Axsome Therapeutics (NASDAQ: AXSM) AXS-12 narcolepsy NDA

Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027, and does not …

Axsome Therapeutics Announces FDA Acceptance of NDA for AXS-12 in Narcolepsy Cataplexy; PDUFA Date Set for May 1, 2027

Axsome Therapeutics has announced that the FDA has accepted its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027. The FDA does not plan to hold an advisory committee meeting for …

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12 (reboxetine) for treating cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027. The FDA does not currently plan to hold an advisory committee meeting for …

Q1 Earnings Outperformers: Somnigroup (NYSE:SGI) And The Rest Of The Consumer Discretionary - Home Furnishings Stocks

Is Sompo Holdings’ (TSE:8630) Ongoing Buyback Quietly Redefining Its Capital Efficiency Story?

YPSN Prognose — Kursziel für 2027

Axsome’s 60% quarter pauses with a 127% Fair Value premium and lighter volume

AXSM slipped 1.8% for the week but remains only 3.7% below its 52-week high, leaving a constructive trend intact while confirmation has become less forceful.

Volume Gainers of June 25, 2026: Ramco Industries, Somi Conveyor, Onward Technologies Lead

Somerset Minerals (ASX: SMM) Taps Shareholders With a 1-for-10 Entitlement Offer to Power Up Its Canadian Copper Hunt

Axsome Therapeutics Inc (AXSM) extends its CNS-drug stock run

The weekly setup remains active, with improved market pressure offset by only moderate relative-strength confirmation.

Axsome Therapeutics Inc (AXSM) pushes 12-week advance to 62.6%

The CNS-focused biotech remains in an active trend, but confirmation is measured rather than broad-based.

Axsome Therapeutics Inc (AXSM) finishes week 9.8% higher in active trend

The CNS-therapy developer’s twelve-week return is now 62.6%, putting the move in a broader biotech rebound rather than a single-week move.

We Think You Can Look Beyond Som Distilleries & Breweries' (NSE:SDBL) Lackluster Earnings

Somnigroup (SGI): Buy, Sell, or Hold Post Q1 Earnings?

Winsome Breweries reports net loss for FY26 as revenue declines

MHHL incorporates Dhananya Capital to acquire Winsome Yarns

SDBL board meeting on May 30 to consider FY26 results

Somi Conveyor FY26 Net Profit Falls to ₹503 Lakh

Somnigroup International (SGI) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Earnings call transcript: Somnigroup’s Q1 2026 EPS beats, stock rises 5.53%

MHHL Board Approves Winsome Yarns Acquisition Under NCLT Resolution Plan

Winsome Yarns Limited Receives NCLT Approval for Resolution Plan

NCLT Approves Winsome Yarns Rs 162.90 Crore Resolution Plan After CoC Meeting

Som Distilleries and Breweries Updates on License Suspension Proceedings

Winsome Yarns Limited Concludes 27th Committee of Creditors Meeting Successfully